Literature DB >> 26775178

Macrophage-mediated inflammation and glial response in the skeletal muscle of a rat model of familial amyotrophic lateral sclerosis (ALS).

Jonathan M Van Dyke1, Ivy M Smit-Oistad1, Corey Macrander1, Dan Krakora1, Michael G Meyer1, Masatoshi Suzuki2.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive motor dysfunction and loss of large motor neurons in the spinal cord and brain stem. While much research has focused on mechanisms of motor neuron cell death in the spinal cord, degenerative processes in skeletal muscle and neuromuscular junctions (NMJs) are also observed early in disease development. Although recent studies support the potential therapeutic benefits of targeting the skeletal muscle in ALS, relatively little is known about inflammation and glial responses in skeletal muscle and near NMJs, or how these responses contribute to motor neuron survival, neuromuscular innervation, or motor dysfunction in ALS. We recently showed that human mesenchymal stem cells modified to release glial cell line-derived neurotrophic factor (hMSC-GDNF) extend survival and protect NMJs and motor neurons in SOD1(G93A) rats when delivered to limb muscles. In this study, we evaluate inflammatory and glial responses near NMJs in the limb muscle collected from a rat model of familial ALS (SOD1(G93A) transgenic rats) during disease progression and following hMSC-GDNF transplantation. Muscle samples were collected from pre-symptomatic, symptomatic, and end-stage animals. A significant increase in the expression of microglial inflammatory markers (CD11b and CD68) occurred in the skeletal muscle of symptomatic and end-stage SOD1(G93A) rats. Inflammation was confirmed by ELISA for inflammatory cytokines interleukin-1 β (IL-1β) and tumor necrosis factor-α (TNF-α) in muscle homogenates of SOD1(G93A) rats. Next, we observed active glial responses in the muscle of SOD1(G93A) rats, specifically near intramuscular axons and NMJs. Interestingly, strong expression of activated glial markers, glial fibrillary acidic protein (GFAP) and nestin, was observed in the areas adjacent to NMJs. Finally, we determined whether ex vivo trophic factor delivery influences inflammation and terminal Schwann cell (TSC) response during ALS. We found that intramuscular transplantation of hMSC-GDNF tended to exhibit less inflammation and significantly maintained TSC association with NMJs. Understanding cellular responses near NMJs is important to identify suitable cellular and molecular targets for novel treatment of ALS and other neuromuscular diseases.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amyotrophic lateral sclerosis (ALS); Glial activation; Inflammation; SOD1(G93A) rats; Skeletal muscle

Mesh:

Substances:

Year:  2016        PMID: 26775178      PMCID: PMC4762214          DOI: 10.1016/j.expneurol.2016.01.008

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  54 in total

Review 1.  Amyotrophic lateral sclerosis and excitotoxicity: from pathological mechanism to therapeutic target.

Authors:  E Bogaert; C d'Ydewalle; L Van Den Bosch
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-07       Impact factor: 4.388

2.  Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins.

Authors:  C L Holness; D L Simmons
Journal:  Blood       Date:  1993-03-15       Impact factor: 22.113

3.  A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis.

Authors:  R M Mitchell; W M Freeman; W T Randazzo; H E Stephens; J L Beard; Z Simmons; J R Connor
Journal:  Neurology       Date:  2008-11-05       Impact factor: 9.910

4.  Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice.

Authors:  Isaac M Chiu; Hemali Phatnani; Michael Kuligowski; Juan C Tapia; Monica A Carrasco; Ming Zhang; Tom Maniatis; Michael C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-20       Impact factor: 11.205

5.  Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man.

Authors:  Lindsey R Fischer; Deborah G Culver; Philip Tennant; Albert A Davis; Minsheng Wang; Amilcar Castellano-Sanchez; Jaffar Khan; Meraida A Polak; Jonathan D Glass
Journal:  Exp Neurol       Date:  2004-02       Impact factor: 5.330

6.  Preferential motor unit loss in the SOD1 G93A transgenic mouse model of amyotrophic lateral sclerosis.

Authors:  J Hegedus; C T Putman; N Tyreman; T Gordon
Journal:  J Physiol       Date:  2008-05-08       Impact factor: 5.182

7.  VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.

Authors:  Mimoun Azzouz; G Scott Ralph; Erik Storkebaum; Lucy E Walmsley; Kyriacos A Mitrophanous; Susan M Kingsman; Peter Carmeliet; Nicholas D Mazarakis
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

Review 8.  Review: The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis.

Authors:  L M Duffy; A L Chapman; P J Shaw; A J Grierson
Journal:  Neuropathol Appl Neurobiol       Date:  2011-06       Impact factor: 8.090

9.  Distinct changes in synaptic protein composition at neuromuscular junctions of extraocular muscles versus limb muscles of ALS donors.

Authors:  Jing-Xia Liu; Thomas Brännström; Peter M Andersen; Fatima Pedrosa-Domellöf
Journal:  PLoS One       Date:  2013-02-26       Impact factor: 3.240

Review 10.  The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Rowan A Radford; Marco Morsch; Stephanie L Rayner; Nicholas J Cole; Dean L Pountney; Roger S Chung
Journal:  Front Cell Neurosci       Date:  2015-10-27       Impact factor: 5.505

View more
  31 in total

1.  Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis.

Authors:  Emiliano Trias; Mariángeles Kovacs; Peter H King; Ying Si; Yuri Kwon; Valentina Varela; Sofía Ibarburu; Ivan C Moura; Olivier Hermine; Joseph S Beckman; Luis Barbeito
Journal:  Glia       Date:  2019-12-20       Impact factor: 7.452

2.  Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS.

Authors:  Emiliano Trias; Sofía Ibarburu; Romina Barreto-Núñez; Valentina Varela; Ivan C Moura; Patrice Dubreuil; Olivier Hermine; Joseph S Beckman; Luis Barbeito
Journal:  JCI Insight       Date:  2017-10-19

Review 3.  Granulocyte-colony stimulating factor (G-CSF): an emerging therapeutic approach for amyotrophic lateral sclerosis (ALS).

Authors:  Mahsa Vafaei Mastanabad; Aref Nooraei; Mahgol Sadat Hassan Zadeh Tabatabaei; Amir Akbari Fakhrabadi; Faria Jafarzadeh
Journal:  Acta Neurol Belg       Date:  2022-06-23       Impact factor: 2.396

Review 4.  Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underlying mechanisms, current status, and prospects.

Authors:  Mohaddeseh Rahbaran; Angelina Olegovna Zekiy; Mahta Bahramali; Mohammadsaleh Jahangir; Mahsa Mardasi; Delaram Sakhaei; Lakshmi Thangavelu; Navid Shomali; Majid Zamani; Ali Mohammadi; Negin Rahnama
Journal:  Cell Mol Biol Lett       Date:  2022-07-16       Impact factor: 8.702

5.  Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS.

Authors:  Emiliano Trias; Peter H King; Ying Si; Yuri Kwon; Valentina Varela; Sofía Ibarburu; Mariángeles Kovacs; Ivan C Moura; Joseph S Beckman; Olivier Hermine; Luis Barbeito
Journal:  JCI Insight       Date:  2018-10-04

6.  Properties of Glial Cell at the Neuromuscular Junction Are Incompatible with Synaptic Repair in the SOD1G37R ALS Mouse Model.

Authors:  Éric Martineau; Danielle Arbour; Joanne Vallée; Richard Robitaille
Journal:  J Neurosci       Date:  2020-08-28       Impact factor: 6.167

Review 7.  Macrophage roles in peripheral nervous system injury and pathology: Allies in neuromuscular junction recovery.

Authors:  Rachel Rios; Albina Jablonka-Shariff; Curtis Broberg; Alison K Snyder-Warwick
Journal:  Mol Cell Neurosci       Date:  2021-01-08       Impact factor: 4.314

8.  FGF23, a novel muscle biomarker detected in the early stages of ALS.

Authors:  Ying Si; Mohamed Kazamel; Michael Benatar; Joanne Wuu; Yuri Kwon; Thaddaeus Kwan; Nan Jiang; Dominik Kentrup; Christian Faul; Lyndsy Alesce; Peter H King
Journal:  Sci Rep       Date:  2021-06-08       Impact factor: 4.379

9.  Transcriptome analysis using patient iPSC-derived skeletal myocytes: Bet1L as a new molecule possibly linked to neuromuscular junction degeneration in ALS.

Authors:  Eileen M Lynch; Samantha Robertson; Claire FitzGibbons; Megan Reilly; Colton Switalski; Adam Eckardt; Sin-Ruow Tey; Koji Hayakawa; Masatoshi Suzuki
Journal:  Exp Neurol       Date:  2021-07-24       Impact factor: 5.330

10.  Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing.

Authors:  Nunzio Vicario; Federica M Spitale; Daniele Tibullo; Cesarina Giallongo; Angela M Amorini; Grazia Scandura; Graziana Spoto; Miriam W Saab; Simona D'Aprile; Cristiana Alberghina; Renata Mangione; Joshua D Bernstock; Cirino Botta; Massimo Gulisano; Emanuele Buratti; Giampiero Leanza; Robert Zorec; Michele Vecchio; Michelino Di Rosa; Giovanni Li Volti; Giuseppe Lazzarino; Rosalba Parenti; Rosario Gulino
Journal:  Cell Death Dis       Date:  2021-06-16       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.